ArticleEJNMMI reports2026
Residual radiopharmaceutical activity in venous access devices during PET and SPECT imaging: a real-world clinical observational cohort study.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn routine practice, radiopharmaceuticals are administered via a newly placed peripheral intravenous catheter (PIVC). However, many patients referred for nuclear medicine imaging already have a semipermanent venous access device in place, such as a central venous catheter, peripherally inserted central catheter, or subcutaneous implantable venous port. Evidence regarding residual radiopharmaceutical activity within preexisting devices-and its potential consequences for SPECT/PET image quality, diagnostic interpretation, and radiation safety-remains limited. This study aimed to quantify device-related residual radiopharmaceutical activity across commonly used access types and to assess any associated clinical impact during image review.
resultsIn this observational cohort study at Skåne University Hospital, Sweden, 167 patient administrations during SPECT or PET imaging between June 2023 and January 2026 were included (40% aged < 18 years). Residual activity was evaluated using ROI/VOI based quantification at the venous access site on reconstructed or planar images. Measurements were performed in an activity meter using PIVCs that had been removed from patients prior to imaging. In an experimental setting, representative venous access devices were flushed under controlled conditions to determine residual activity fraction. Residual activity was expressed both as absolute activity (MBq) and as the percentage of the administered activity. Across 214 measurements including 13 radiopharmaceuticals, residual activity was generally low: only 3.3% of the measurements (7/214) exceeded 5% of the administered activity. The highest absolute residual activity was 31 MBq ([
conclusionsIn this real-world cohort, residual radiopharmaceutical activity within preexisting venous access devices was generally low and showed no discernible impact on visual clinical SPECT or PET interpretation. Prospective studies including a broader range of tracers, access devices, and quantitative endpoints are needed to more fully characterize the clinical implications of residual activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.